Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.

This study observed that trichoscopic changes associated with EGFRI treatment include pili torti and asymmetric hyperpigmented fusiform widening, along with dermoscopic skin manifestations such as scale and branching vessels.

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.

In this study, a combined therapy of nicotinamide and green tea polyphenols was reported to improve EGFR inhibitor-related skin toxicity and patient quality of life, suggesting it merits further investigation.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

This case report describes a 64-year-old man with advanced colorectal cancer developing cutaneous side effects from panitumumab, highlighting the importance of early diagnosis and treatment to improve quality of life and therapy continuation.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This study elucidates a mechanism for acne-like skin toxicity caused by EGFR/MEK inhibitors, involving an interaction with skin bacteria to trigger inflammation, which supports existing antibiotic treatment practices.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

This case report details an occurrence of PRIDE syndrome accompanied by lumbosacral hypertrichosis.

This symposium review highlights past, present, and future developments in skin research, celebrating the work of Prof. Johanna Brandner and Dr. Peter Arne Gerber, without reporting new clinical results.

This article discusses the clinical manifestations and management strategies of skin side effects from epidermal growth factor receptor inhibitors, but reports no new clinical findings.

This study observed that overexpression of TGF-alpha in transgenic mice led to thicker epidermis and stunted hair growth, particularly in regions with normally thick skin and low hair density.

In this study, researchers found that YAP and TAZ, when localized in the nucleus of basal layer cells, are crucial for skin regeneration and hair growth, with their loss leading to slower cell proliferation, hair loss, and impaired wound healing in mice.

Blocking EGFR in mice causes hair loss and skin changes.

This review discusses the effects of the epidermal growth factor receptor system on skin biology and pathology, relying on animal models to analyze roles in cellular processes, wound healing, and tumorigenesis, but reports no new results.

This review discusses the role of Hedgehog signaling in basal cell carcinoma development and highlights genetic mouse models and potential targeted therapies, but reports no new clinical results.

In this study, mice engineered to express human EGFR showed tissue-specific growth defects and neurodegeneration rescue, but developed severe heart issues and accelerated bone cell differentiation.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

In this study, disrupting the epidermal growth factor receptor in mice led to abnormal hair and skin development, characterized by disorganized hair follicles and systemic disease, providing a model for understanding EGFR's role in skin biology.

This review discusses the role of the EGF receptor/ligand system in skin homeostasis and its implications for keratinocyte stem cells and reports no new clinical results.

This study found that continuous expression of epidermal growth factor in transgenic mice prevented hair follicles from entering the catagen phase, implicating EGF as a crucial regulator in hair cycle progression.

This paper describes the PRIDE syndrome associated with epidermal growth factor receptor inhibitors but reports no new clinical results.